Popularly prescribed pain drug can increase the risk of dementia by up to 40%, reveals study
Tired of too many ads? go ad free now
With every drug having some types of side effects, the ones produced by taking this one include dizziness, drowsiness, headaches and nausea. While these might be more adaptable side effects that can be dealt with easily, a new study has revealed one side effect of the consumption of gabapentin that has more long-term effects than ever known before.
Case Western University in Cleveland performed a
to find that gabapentin can significantly increase the risk of dementia and mild cognitive impairment in people consuming it for lower chronic back pain.
'Our findings indicate an association between gabapentin prescription and dementia or cognitive impairment within 10 years. Moreover, increased gabapentin prescription frequency correlated with dementia incidence,' wrote the study authors in the study published in the journal Regional Anesthesia & Pain Medicine.
Does gabapentin really increase the risk of dementia?
Image credits: X
In order to carry out the research, the researchers examined the records of over 26,400 patients who had been prescribed gabapentin for persistent low back pain between 2004 and 2024 and 26,400 patients who had not been prescribed the drug.
After considering differentiating factors such as patient demographics, medical history and use of other painkillers, the researchers revealed that those who had received 6 or more gabapentin prescriptions were 29% more likely to be diagnosed with dementia. These people were 85% more likely to be diagnosed with mild cognitive impairment within 10 years of back pain diagnosis.
While dementia typically affects older adults over the age of 65, due to the consumption of gabapentin, the risk of dementia more than doubled among people between the ages of 35-49.
Tired of too many ads? go ad free now
Additionally, the risk of mild cognitive impairment more than tripled. Similar effects were seen in people between 50-64 years old.
Here, the frequency of use was a deciding factor as well. Those with 12 or more prescriptions were 40% more likely to develop dementia and 65% more likely to develop mild cognitive impairment as compared to those who had 3-11 prescriptions.
Gabapentin was approved by the FDA in 1993 to control partial seizures in epilepsy patients older than 12.
It was initially considered to have a low potential for abuse or dependence.
However, recently various cases of its side effects have been on the rise.
published in Pain Medicine highlighted how gabapentin exposure was associated with hospitalisation for all ages, even at low doses.
The results of the study associating gabapentin with a higher risk of dementia support the monitoring of adult patients prescribed the drug to monitor their potential cognitive decline.
Along with drug consumption, other risks of dementia are traumatic brain injury, untreated hearing loss, depression, high blood pressure, diabetes, obesity and smoking. The ideal way to reduce these risks is to stop smoking and alcohol consumption, have a healthy diet and regular exercise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Dubai pistachio chocolate spread linked to salmonella outbreak: What you need to know
A popular pistachio-cocoa spread sold in the US has been linked to a Salmonella outbreak, causing illness in several people, including one who was hospitalised. The spread, made by a Turkish company and sold at World Market stores, is now being recalled nationwide. Tired of too many ads? go ad free now Salmonella is a harmful bacterium that can cause stomach pain, diarrhoea, fever, and vomiting. It can be very serious, especially for young children, older adults, and people with weak immune systems Salmonella found in popular pistachio cocoa spread sold nationwide According to reports, on July 14, 2025, World Market and the FDA announced a recall after the Minnesota Department of Agriculture detected Salmonella during routine testing. The recall involves Emek Gıda's Spread Pistachio Cacao Cream with Kadayif, a pistachio-cocoa spread manufactured by a Turkish company and sold at World Market stores across more than 30 US states, including Alabama, California, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington, and Wisconsin. Source: The CDC later confirmed four cases of illness linked to this pistachio cream product, including one hospitalisation. Consumers who have purchased the affected 9.7 oz jars labeled with 'Dubai' are strongly advised not to consume the product. Salmonella is a harmful bacterium that can cause serious and sometimes fatal infections, especially in young children, the elderly, and individuals with weakened immune systems. What is Salmonella and why is it dangerous Salmonella is a common bacterial infection that affects the digestive system. It is often caused by consuming contaminated food or beverages. Symptoms include diarrhea, stomach cramps, fever, nausea, and vomiting. While many people recover without treatment, Salmonella infections can be severe, especially in young children, elderly individuals, and those with weakened immune systems. In serious cases, the infection can lead to hospitalisation or even life-threatening complications. Tired of too many ads? go ad free now This recent outbreak linked to the pistachio-cocoa spread has raised concerns about food safety standards and consumer awareness. Symptoms to watch for after consuming the Dubai chocolate spread If you or your family have consumed the recalled pistachio-cocoa spread, watch for symptoms such as diarrhea, abdominal pain, fever, and vomiting. These signs typically appear 6 hours to 6 days after infection. If symptoms are severe or persistent, especially in vulnerable groups like children or the elderly, seek medical attention immediately. Early diagnosis and treatment can help reduce complications and speed up recovery. What to do if you have a Salmonella infection If you suspect you have a Salmonella infection, contact your healthcare provider promptly. Diagnosis is typically confirmed through stool tests, and treatment may include hydration and, in some cases, antibiotics. It's also important to report your illness to local health departments to help track outbreaks and prevent further spread. Early medical intervention can prevent serious health outcomes. Also read|
Time of India
7 hours ago
- Time of India
Can cancer drugs treat Alzheimer's? New study thinks so
Alzheimer's disease, a progressive neurodegenerative disorder that primarily affects memory and cognitive functions, is the most common cause of dementia, accounting for 60-70% of dementia cases. As per Alzheimer's Association, in 2025, global Alzheimer's statistics indicate a significant prevalence of the disease, with projections estimating that over 7 million Americans will be living with Alzheimer's dementia. Globally, it is estimated that someone develops dementia every three seconds, and the number of people living with dementia is expected to reach 78 million by 2030. The progressive neurodegenerative disorder, long considered a therapeutic dead end, may soon find some hope of cure in an unlikely ally: cancer drugs. Recent research reveals that several oncology medications, originally designed to fight tumors, have shown promise in targeting key pathways of Alzheimer's disease (AD), from protein aggregation to neuroinflammation and metabolic dysfunction. Let's delve deeper into the newest discovery of the silver lining. The medical breakthrough: Scientists are exploring cancer drugs as a potential way to tackle Alzheimer's disease, given that the options for treatment are quite limited. As cases of Alzheimer's continue to rise in the U.S. and around the world due to an aging population, there still isn't a cure. Efforts to create new treatments that actually slow the disease's progression have mostly fallen short. Currently, only two drugs, Leqembi and Kisunla, are approved by the FDA to slow down early Alzheimer's, but their effectiveness is very limited. Many pharmaceutical companies have even stopped developing Alzheimer's drugs after unsuccessful trials, while others are experimenting with existing medications, including popular weight loss drugs. Researchers at the University of California, San Francisco, have taken a different approach. They searched through a database of over 1,300 various drugs, like antipsychotics and chemotherapy drugs, to find ones that could be repurposed for Alzheimer's treatment. Their study, published in the journal Cell , highlighted two cancer drugs that showed promise in reducing Alzheimer's risk. When tested together on mice, these drugs appeared to slow or even reverse Alzheimer's symptoms. One drug is typically used for breast cancer, and the other works against colon and lung cancer. Alzheimer's is known to cause significant changes in gene expression in the brain, which can disrupt brain function and lead to memory loss. From their database, fewer than 90 drugs successfully reversed markers related to Alzheimer's in human brain cells. Of these, five drugs seemed particularly effective in lowering Alzheimer's risk for actual patients, and the researchers focused on two FDA-approved cancer drugs to test in mice. According to the findings, letrozole, a breast cancer drug, appeared to influence gene expression in nerve cells, while irinotecan, used for colon and lung cancer, affected glial cells, which support the nervous system. Alzheimer's can damage nerve cells and trigger an overgrowth of glial cells, leading to brain inflammation. Interestingly, past studies have shown that breast cancer patients on letrozole had a lower chance of developing Alzheimer's, and colorectal cancer survivors treated with irinotecan also showed decreased risk, adding to the excitement around these findings. The groundbreaking findings: Researchers have been testing a combination of two cancer drugs in mice and found some promising results: the combo reversed brain degeneration and improved memory in mice showing signs of Alzheimer's. However, because what works in mice doesn't always work in humans, they plan to test these drugs in a clinical trial with Alzheimer's patients. Dr. Yadong Huang, a co-author of the study and a neurology professor at UCSF, noted the advantages of repurposing existing drugs: 'Developing a new drug can take hundreds of millions, or even billions, of dollars, and on average takes more than 10 years. For this repurposed drug, usually, it just takes two or three years, and then you can go to the clinical trial, and the cost is much, much lower.' Despite this progress, he acknowledged, as reported by NBC News, 'We still haven't generated or produced any very effective drugs that can really slow down dramatically the cognitive decline. ' Alzheimer's remains a complex disease, and its exact cause is still a mystery. Currently, it isn't clear why these cancer drugs might help with Alzheimer's. One idea is that the breast cancer drug reduces estrogen production, which controls many genes. Another theory is that the colon and lung cancer drug might reduce inflammation in the brain by stopping glial cells from multiplying. Dr. Melanie McReynolds, a biochemistry assistant professor at Pennsylvania State University, who wasn't involved in this study, added another angle. Her research suggests that another cancer drug can help Alzheimer's by regulating glucose metabolism, which is how cells generate energy. 'With aging, with stress, with diseases, that line of communication is disrupted,' she explained. She believes the drug combo could reverse metabolic decline, calling it 'the secret for contributing to better outcomes with Alzheimer's. ' What's ahead: Cancer drug repurposing opens a transformative chapter in Alzheimer's treatment, where repurposing anticancer agents allows researchers to exploit existing toxicity and pharmacokinetic data, potentially accelerating human testing and reducing development costs. While these findings are exciting, the potential side effects need to be carefully considered. Letrozole can cause hot flashes, and irinotecan may lead to severe diarrhea. 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota cautioned. 'It's not that it's a slam dunk.' Reduced risk of Alzheimer's disease linked to target protein for diabetes, as per a study
India Today
13 hours ago
- India Today
Children's Hospital LA halts use of Sarepta's gene therapy for all patients
Children's Hospital Los Angeles has paused the use of Sarepta Therapeutics' gene therapy Elevidys for all patients with muscular dystrophy, following recent US Food and Drug Administration (FDA) actions that raised safety a statement Monday, Children's Hospital LA said the pause has been communicated to affected patient families while it awaits any further determination by the FDA. The hospital is amongst more than 70 nationwide authorised to administer Elevidys. Five other major children's hospitals asked to comment on whether they planned to continue use of the gene therapy did not immediately respond, Reuters decision, effective July 18, comes after the FDA asked Sarepta last week to voluntarily halt shipments of the treatment. The request followed the death of a muscular dystrophy patient who received a different, experimental gene therapy. Sarepta has so far refused to comply, stating it will "continue making the treatment available to ambulatory patients." Elevidys was granted full FDA approval last year for children with Duchenne Muscular Dystrophy who can still walk, and received conditional approval for non-ambulatory patients. However, Sarepta suspended use in non-ambulatory cases in June, after two teenagers died of liver failure following FDA's recent request reignited scrutiny of the therapy's safety profile. Shares of Sarepta, down about 90% year-to-date, fell 5% on Monday to close at $13.32 on Nasdaq.- EndsWith inputs from Reuters
